Human Cathepsin B / CTSB Protein, His Tag (active enzyme, MALS verified)
分子別名(Synonym)
CTSB,CPSB,APPS
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human Cathepsin B, His Tag (CTB-H5222) is expressed from human 293 cells (HEK293). It contains AA Arg 18 - Ile 339 (Accession # P07858-1 (L26V)).
Predicted N-terminus: Arg 18 & Leu 80
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The Human Cathepsin B will be further processed into mature form (Leu 80-Ile 339). The protein has a calculated MW of 36.7 kDa (pro-form) and 29.5 kDa (mature-form). The protein migrates as 42-50 kDa and 34 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH8.0 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
組織蛋白酶B(CTSB)也稱為APP分泌酶(APPS),CPSB是屬于肽酶C1家族的酶促蛋白。組織蛋白酶B/CTSB被合成為前酶。去除信號(hào)肽后,無(wú)活性的酶原會(huì)進(jìn)行進(jìn)一步的修飾,包括去除前區(qū)以產(chǎn)生活性酶。組織蛋白酶B/APP的催化活性包括:對(duì)肽鍵具有廣泛特異性的蛋白質(zhì)水解;優(yōu)先切割小分子底物中的-Arg-Arg-Xaa鍵(因此不同于組織蛋白酶L);除了作為內(nèi)肽酶外,還顯示肽基二肽酶活性,釋放C端二肽。組織蛋白酶B/CPSB作為一種巰基蛋白酶,被認(rèn)為參與蛋白質(zhì)的細(xì)胞內(nèi)降解和更新,也與腫瘤的侵襲和轉(zhuǎn)移有關(guān)。組織蛋白酶B的過(guò)度表達(dá)與食管腺癌和其他腫瘤有關(guān)。
關(guān)鍵字: Cathepsin B;Cathepsin B蛋白;CTSB重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。